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Background: The phase II multicenter, randomized, open label, therapeutic trial (ISS T-002, Clinicaltrials.gov
NCT00751595) was aimed at evaluating the immunogenicity and the safety of the biologically active HIV-1 Tat protein
administered at 7.5 or 30 μg, given 3 or 5 times monthly, and at exploring immunological and virological disease biomarkers.
The study duration was 48 weeks, however, vaccinees were followed until the last enrolled subject reached the 48 weeks.
Reported are final data up to 144 weeks of follow-up. The ISS T-002 trial was conducted in 11 clinical centers in Italy on
168 HIV positive subjects under Highly Active Antiretroviral Therapy (HAART), anti-Tat Antibody (Ab) negative at baseline,
with plasma viremia <50 copies/mL in the last 6 months prior to enrollment, and CD4+ T-cell number ≥200 cells/μL.
Subjects from a parallel observational study (ISS OBS T-002, Clinicaltrials.gov NCT0102455) enrolled at the same clinical
sites with the same criteria constituted an external reference group to explore biomarkers of disease.
Results: The vaccine was safe and well tolerated and induced anti-Tat Abs in most patients (79%), with the highest
frequency and durability in the Tat 30 μg groups (89%) particularly when given 3 times (92%). Vaccination promoted
a durable and significant restoration of T, B, natural killer (NK) cells, and CD4+ and CD8+ central memory subsets.
Moreover, a significant reduction of blood proviral DNA was seen after week 72, particularly under PI-based regimens
and with Tat 30 μg given 3 times (30 μg, 3x), reaching a predicted 70% decay after 3 years from vaccination with a
half-life of 88 weeks. This decay was significantly associated with anti-Tat IgM and IgG Abs and neutralization of
Tat-mediated entry of oligomeric Env in dendritic cells, which predicted HIV-1 DNA decay. Finally, the 30 μg, 3x group
was the only one showing significant increases of NK cells and CD38+HLA-DR+/CD8+ T cells, a phenotype associated
with increased killing activity in elite controllers.
Conclusions: Anti-Tat immune responses are needed to restore immune homeostasis and effective anti-viral responses
capable of attacking the virus reservoir. Thus, Tat immunization represents a promising pathogenesis-driven intervention
to intensify HAART efficacy.
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HIV-1 persistence in reservoirs is associated with im-
mune activation and T and B cell dysfunction, which
represent the unmet needs of HAART [1-5], and are the
cause of increased patients’ morbidity and mortality due
to non-AIDS related diseases [1,3]. In fact, residual virus
replication and cell-to-cell virus transmission still occur
under a suppressive HAART and sustain the replenish-
ment of HIV-1 reservoirs [5-7]. As a consequence, no re-
duction of blood HIV-1 DNA is observed after a few years
of suppressive HAART, although levels appear to be lower
in Protease Inhibitors (PI)- than in Non-Nucleoside Re-
verse Transcriptase Inhibitors (NNRTI)-treated patients
[8]. This HAART-resistant virus reservoir and associated
disorders represent a major problem in the clinical man-
agement of HIV-infected patients and a serious econom-
ical burden for the National Health Systems.
Intervention strategies aimed at attacking the virus
reservoir and intensifying HAART efficacy have failed to
date [9-12]. However, a “pathogenesis-driven” approach
targeting viral products responsible of immune dysregu-
lation, virus transmission and maintenance of virus res-
ervoirs should be able to intensify HAART.
Tat is a key HIV virulence factor, which plays pivotal
roles in virus gene expression, replication, transmission
and disease progression [13-20]. Tat is produced very
early upon infection [13-15] and continue to be expressed
under HAART [21-23], is released extracellularly, accu-
mulates in tissues, and exerts effects on both the virus and
the immune system [15-25] that make it an optimal candi-
date for therapeutic immunization and HAART intensifi-
cation [22,26-28].
Extracellular Tat induces HIV co-receptor expression
[29], activates virus replication and efficiently increases
virus transmission to neighbor cells [15,23,30-32]. Fur-
ther, extracellular Tat, which has been shown to be
present on highly purified virions [33], binds Env spikes
present on virus particles forming a virus entry complex
that favors infection of dendritic cells (DC) and trans-
mission to T cells, key components of the virus reservoir
[32]. This occurs by redirecting virus entry from the ca-
nonical receptors to RGD-binding integrins (α5β1, αvβ3,
αvβ5) that Tat uses as receptors to enter DC [32]. Of
note, by binding the Env C-C chemokine receptor type 5
co-receptor binding sites, Tat shields Env from anti-HIV
Abs, thus inhibiting virus neutralization, which, however,
can be restored and further increased by anti-Tat Abs
[32]. Accordingly, mucosal immunization of monkeys
with combined Tat and oligomeric Env protected ani-
mals from intrarectal virus challenge, blocking virus
spread from the rectum to local lymph nodes [32]. Thus,
Tat-specific Abs appear to be key to prevent HIV acqui-
sition and spreading. Indeed, Tat vaccination in nonhu-
man primates can prevent or control infection withpathogenic SHIV [34,35], as recently confirmed by others,
and found to correlate with anti-Tat Abs [36]. Notably,
anti-Tat Abs are uncommon in natural infection [37] and,
when present, correlate with the asymptomatic state,
higher CD4+ T cell number and lower viral load, and with
reduced or absent disease progression, particularly in
infection with B clade viruses and when antibodies are
persistent and characterized by multiple isotypes and high
titers [38-41].
Moreover, Tat alters the homeostatic regulation of the
immune system promoting an excessive and improper
immune stimulation that prepares target cells for virus
propagation while disabling an effective immune control.
For example, extracellular Tat induces DC maturation
[24,42] toward a Th1-type immune response, activates T
cells independently from the engagement of the T-cell
receptor [23,30], activates the immunoproteasome
leading to alterations of cytotoxic T cell epitope pres-
entation in CD8+ T cells [25,43], while skewing the re-
sponse towards an “effector” and “effector memory”
phenotype [44,45], which is accompanied by a loss of B
cells [45]. CD8+ T cell hyperactivation is associated
with functional deficit and is followed by effector cell
apoptosis [46-49]. Notably, all these alterations are hall-
marks of the chronic immune dysregulation observed in
HIV-infected patients, which is only partially reverted by
HAART [46-48].
Thus, the immune dysregulation induced by Tat ap-
pears to be pivotal in the establishment and maintenance
of HIV infection, since it increases target cell recruit-
ment, permissivity, virus reactivation and transmission,
while disarming the host immune defense. This suggested
that targeting Tat represents a pathogenesis-driven inter-
vention to intensify HAART efficacy.
After the successful completion of randomized, pla-
cebo controlled, phase I trials with the biologically active
HIV-1 Tat protein [26-28], a open-label randomized
phase II trial with Tat was conducted in 168 anti-Tat
Ab-negative, virologically suppressed HAART-treated
subjects (ISS T-002, ClinicalTrials.gov NCT00751595).
Seventy-nine subjects of the observational study (ISS
OBS T-002, Clinicaltrials.gov NCT0102455) conducted
in parallel at the same centers served as an external ref-
erence group for immunological and virological disease
biomarkers, according to regulatory requirements [50].
Results of an exploratory interim analysis [22], up to
48 weeks, on 87 trial subjects which completed the treat-
ment phase indicated earlier that Tat immunization not
only was safe and immunogenic, but had also a positive
impact on immune activation and T and B cell dysregula-
tion that persist under effective antiretroviral treatment.
Here we report the results of immunogenicity and
safety (primary and secondary endpoints of the trial,
respectively) and of the immunological and virological
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168 individuals after trial completion (48 weeks), as well




Two hundred seventy-two volunteers were assessed for
eligibility and 103 were excluded from the enrollment:
94 volunteers either did not meet inclusion criteria or
met exclusion criteria, 8 declined to participate and 1 in-
dividual was lost to follow up (Figure 1).Figure 1 Study flow chart. Two hundred seventy-two HAART-treated pat
excluded from the study (n = 94 for either not meeting the inclusion criter
was lost to follow-up). Thus, 169 subjects were randomized to one of the 4
concomitant treatment with a contraindicated medication, therefore 168 v
population). Since 11 subjects (from the different treatment groups) receive
antiretroviral therapy, 155 subjects were considered for the analyses of immOne hundred sixty-eight HIV-1 infected HAART-
treated, anti-Tat Ab negative adults were allocated to
intervention and analyzed for safety. Since 11 subjects
received less than 3 immunizations and 2 individuals
were not therapy compliant, the immunogenicity popu-
lation consisted of 155 patients randomized to receive
the biologically active HIV-1 Tat protein at 7.5 μg or
30 μg, given 3 (3x) or 5 (5x) times at monthly intervals,
respectively (Figure 1).
Seventy-nine anti-Tat Ab negative HAART-treated
subjects enrolled with the same criteria at the same sites
in the parallel observational study ISS OBS T-002 andients were assessed for eligibility. One hundred three patients were
ia or for meeting exclusion criteria; n = 8 declined to participate, and 1
treatment groups. One subject was excluded after randomization for
olunteers were allocated to intervention and analyzed for safety (safety
d less than 3 immunizations and 2 subjects were non compliant with
unogenicity (immunogenicity population).
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sented the external control group for disease biomarkers
[50]. Baseline demographic and clinical characteristics of
ISS T-002 and ISS OBS T-002 participants were compar-
able, although significant differences were detected for CD4
nadir and in the percentage of CD4+ T cells (Table 1). Since
the trial protocol was amended during the study to include
more immune compromised subjects (see Methods), both
the pre- and post-amendment trial populations were also
compared with OBS subjects (Table 2). The ISS T-002
study population after the protocol amendment did not
show any significant difference as compared to the OBS
group. No differences were observed at baseline in the
demographic and clinical characteristics of the ISS T-002
study participants according to treatment groups (Table 3).Table 1 Baseline characteristics of the ISS T-002 and ISS
OBS T-002 study participants
ISS T-002 ISS OBS T-002 p-valued
(n = 155) (n = 79)
Age
Mean ± s.d.a 41 ± 7 42 ± 6 0.6323
Range 24-55 24-55
Gender
Male 83% 75% 0.1200
Female 17% 25%
CD4+ nadir (cells/μl)
Mean ± s.d. 308 ± 133 219 ± 140 <0.0001
Range 14-846 2-612
CD4+ (cells/μl)
Mean ± s.d. 639 ± 220 657 ± 271 0.5450
Range 212-1490 208-1527
CD4+ (%)
Mean ± s.d. 33 ± 8 31 ± 8 0.0257
Range 14-61 12-52
HIV RNA (copies/ml) <50b <50c
Years from diagnosis of HIV
Mean ± s.d. 9 ± 6 11 ± 7 0.1789
Range 1-25 1-24
Years from HAART initiation
Mean ± s.d. 6 ± 4 6 ± 5 0.4984
Range 0-19 0-19
Current HAART regimen
NNRTI-based or NRTI 68% 62% 0.3305
PI-based 32% 38%
n indicates the number of evaluable individuals; aStandard deviation; bFive
subjects had values >50 copies/ml (between 58 and 91); cFour subjects had
values >50 copies/ml (between 64 and 118);
dt-test was applied for continuous variables, Chi-square test was applied for
categorical variables.Values of immunological and virological biomarkers at
study entry for ISS T-002 and ISS OBS T-002 participants
were comparable and no significant differences were de-
tected except for B cell numbers (Table 4). Lower but
still significant differences as compared to OBS subjects
were still observed for B cells in trial subjects after the
protocol amendment (Table 5). Nevertheless, in all cases
B cell counts at baseline were well within the normal
range in both T-002 and OBS subjects. No significant
differences between trial subjects both pre- and post-
amendment and OBS subjects were detected for the
other immunological and virological parameters at base-
line (Table 5).
Immunogenicity
Tat immunization induced anti-Tat Abs in most vacci-
nees (79%), with the highest frequency in the Tat 30 μg
groups (89%) and particularly after 3 administrations
(92%) as compared to the 7.5 μg arms (70%) (Table 6
and Figure 2A). Statistically significant odds ratios were
detected for Tat 30 μg 3x or 5x as compared to the ref-
erence (Tat 7.5 μg, 3x), whereas no differences were ob-
served between 7.5 μg 5 x and the reference (Table 6).
In the Tat 30 μg groups Abs persisted significantly lon-
ger, as compared to the Tat 7.5 μg groups (Figure 2B).
The 30 μg doses were also more effective at inducing
anti-Tat Abs of different isotypes (Figure 2C, D), and
peak IgG titers (Figure 2E, F). Tat immunization also in-
creased the percentage of responders and intensity of
anti-Tat cellular responses, including IFN-γ, IL-4, IL-2
production and CD4+-, CD8+-T cell proliferation, as
compared to baseline (Table 6 and Figure 3A, B) without
significant differences among the treatment groups. Cel-
lular responses to Tat were also present in OBS subjects
(Figure 3C, D).
Safety
Immunization with Tat was safe and well tolerated with-
out any notable dose-dependent relationship. The ad-
verse events (AE) reported during the study indicated
that the Tat vaccine may induce mild injection site reac-
tions, and systemic effects, which were generally well
tolerated. A total of 103 patients experienced at least
one AE during the 48 weeks of the study and the mean
number of AE reported per patient was 3.63 (range 1–23).
These AE were mainly mild and unrelated to the study
treatment (Table 7). General disorders and administration
site reactions were the most frequently reported AE with a
possible, probable or definite relationship to study treat-
ment (Additional file 1: Table S1). Serious AE were re-
corded in 10 vaccinees. For 8 of them the events were
judged “unrelated (n. 6) or unlikely related (n. 2)” to the
study drug. The remaining 2 patients with serious AE
manifested in one case “possibly related” peripheral











(n = 87) (n = 81) (n = 79) p-valueb p-valueb
Age
Mean ± s.d.a 41 ± 7 42 ± 7 42 ± 6 0.2963 0.8043
Range 26-54 23-55 24-55
Gender
Male 78% 86% 75% 0.5977 0.0604
Female 22% 14% 25%
CD4+ nadir (cells/μl)
Mean ± s.d. 352 ± 114 251 ± 131 219 ± 140 <0.0001 0.1131
Range 252-846 14-585 2-612
CD4+ (cells/μl)
Mean ± s.d. 693 ± 210 585 ± 215 657 ± 271 0.4018 0.0668
Range 425-1490 144-1250 208-1527
CD4+ (%)
Mean ± s.d. 34 ± 7 32 ± 8 31 ± 8 0.0033 0.2596
Range 19-53 14-61 12-52
Years from diagnosis of HIV
Mean ± s.d. 9 ± 6 9 ± 7 11 ± 7 0.1583 0.3703
Range 1-23 1-25 1-24
Years from HAART initiation
Mean ± s.d. 6 ± 4 7 ± 5 6 ± 5 0.2552 0.9073
Range 0-19 0-19 0-19
Current HAART regimen
NNRTI-based or NRTI 75% 56% 62% 0.0784 0.3434
PI-based 25% 44% 38%
n indicates the number of individuals; aStandard deviation; bt-test was applied for continuous variables, Chi-square test was applied for categorical variables.
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weakness, tongue paresthesia associated with retrosternal
constriction) which resolved after 10 days; in the other
case a “probably related” right Bell’s paralysis was diag-
nosed which resolved within 3 months. These events were
evaluated by the Data Safety Monitoring Board (DSMB)
overseeing the study and judged as manifestations occur-
ring more frequently in HIV-infected patients and also
relatively common after the administration of different
commercial vaccines. After the 48 weeks of the study, no
relevant AE were recorded. Three subjects experienced
serious AE judged as “unrelated” to the study treatment
that included 2 subjects with hepatic enzymes increase
and S. aureus infection and abdominal pain, respectively,
which were completely resolved within 4 months, and a
third subject with ischemic hemianopsia which was re-
solved with sequelae.
Based on the overall safety data the DSMB judged the
Tat vaccine as safe and well tolerated.Immune restoration
A significant increase of CD4+ T cell number was ob-
served early after Tat immunization, peaking at year 2
(up to about 100 cells/μl increase p < 0.0001) and
persisting at year 3, while no significant changes from
baseline were detected in OBS subjects during the 3 years
of follow up (Figure 4A, B), as observed previously for
successfully treated subjects after years of therapy (mean
of 6 years for both ISS T-002 and OBS subjects) [51-53].
At the same time, Tat immunization maintained stable
levels of CD8+ T cells, which, in contrast, progressively
decreased in OBS subjects, particularly at year 2 and 3
(Figure 4C, D), as observed earlier during HAART
[54-56]. An early and significant increase of B cells was
also induced by Tat immunization that reached the high-
est value at year 3, whereas a trend to reduction was
observed in OBS subjects (Figure 4E, F). Natural killer
(NK) cell numbers were also significantly increased in
vaccinees at year 2 and 3, while no significant changes
Table 3 Baseline characteristics of the ISS T-002 study participants by treatment groups
Tat 7.5 μg, 3x Tat 7.5 μg, 5x Tat 30 μg, 3x Tat 30 μg, 5x
(n = 40) (n = 40) (n = 38) (n = 37)
Age
Mean ± s.d.a 40 ± 7 41 ± 6 43 ± 5 42 ± 8
Range 24-54 29-55 33-55 26-54
Gender
Male 73% 90% 79% 92%
Female 27% 10% 21% 8%
CD4+ nadir (cells/μl)
Mean ± s.d. 287 ± 74 321 ± 139 337 ± 165 285 ± 136
Range 97-450 76-699 15-846 14-585
CD4+ (cells/μl)
Mean ± s.d. 660 ± 216 644 ± 233 617 ± 214 632 ± 222
Range 293-1490 214-1382 212-1362 286-1250
CD4+ (%)
Mean ± s.d. 34 ± 7 33 ± 7 33 ± 7 33 ± 10
Range 22-53 20-46 19-47 14-61
Years from diagnosis of HIV
Mean ± s.d. 8 ± 6 10 ± 6 10 ± 7 9 ± 7
Range 1-21 2-25 1-23 1-24
Years from HAART initiation
Mean ± s.d. 5 ± 4 6 ± 4 7 ± 5 7 ± 5
Range 0-19 0-19 0-18 1-17
Current HAART regimen
NNRTI-based or NRTI 58% 75% 66% 76%
PI-based 42% 25% 34% 24%
n indicates the number of evaluable individuals; aStandard deviation.
No significant differences were detected among treatment groups at baseline.
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tern of B and NK cells seen in OBS is similar to what
has been reported during HAART [57,58].
In vaccinees, changes of CD4+ and CD8+ T cells, B
and NK cells were comparable with both drug regimens
(NNRTI/NRTI- or PI-based) (Figure 5). In contrast, the
decreases of CD8+ T cells and B cells observed in OBS
subjects were differently affected by the drug regimens.
In particular, the CD8+ T cell loss was more profound,
reaching statistical significance, under PI-based regimens
(Figure 5D), whereas the B cell reduction occurred
mostly under NNRTI/NRTI regimens (Figure 5F). Thus,
Tat immunization during HAART restores T, B and NK
cell numbers as compared to HAART alone.
Of note, the increase of CD4+ T cells after vaccination
was independent from the nadir and at year 3 subjects
with nadir ≤250 cells/μl had increases greater, although
not significantly different, than those with a nadir >250
cells/μl (increase of 132 cells/μl p = 0.0012 vs 85/μl cells
p = 0.0003, respectively) (Figure 6A).The increase of CD4+ T cells and the maintenance of
CD8+ T cells after vaccination were associated with a
statistically significant increase of CD4+/CD8+ ratio
overtime (Figure 6B). This was observed also in OBS
subjects. However, in vaccinees, it was due to the increase
of CD4+ T cells (Figure 4A), whereas in OBS subjects it
was due to the decrease of CD8+ T cells (Figure 4C), as re-
ported earlier to occur during HAART [54-56].
In vaccinees, changes in CD4+ and CD8+ T cells were
accompanied by an early, durable and statistically signifi-
cant restoration of functional subsets, while few or no
changes were observed in OBS subjects (Figure 7). In
particular, early (year 1) and durable (up to year 3) in-
creases of CD4+ central memory T cells (Tcm) occurred
in vaccinees. This was associated with decreases of naïve
and effector memory T cells (Tem), which, however, in
most cases did not reach statistical significance (Figure 7A).
No significant changes from baseline of CD4+ T cell subsets
were seen in OBS subjects (Figure 7B) as reported in other
studies [52,53].
Table 4 Immunological and virological parameters at baseline in ISS T-002 and ISS OBS T-002 study participants
ISS T-002 ISS OBS T-002 p-valueb
n Mean ± s.d.a n Mean ± s.d.a
Phenotype (cells/μL)
CD4+ 152 661 ± 231 79 700 ± 300 0.2671
CD8+ 152 802 ± 393 79 881 ± 360 0.1295
B 152 241 ± 121 79 307 ± 164 0.0006
NK 152 232 ± 152 79 268 ± 193 0.1231
CD4+ subsets (%)
Naïve 94 31 ± 14 31 28 ± 13 0.7057
Effector memory 94 22 ± 12 31 20 ± 8 0.5304
Central memory 94 47 ± 10 31 51 ± 9 0.2810
CD8+ subsets (%)
Naïve 94 26 ± 11 31 30 ± 11 0.0835
Effector memory 94 52 ± 13 31 47 ± 13 0.0756
Central memory 94 22 ± 10 31 23 ± 9 0.7302
HIV DNA (log10 copies/10
6 CD4+cells) 142 3.1 ± 0.5 54 3.0 ± 0.5 0.4381
Tat 7.5 μg, 3x 36 3.1 ± 0.6
Tat 7.5 μg, 5x 36 3.0 ± 0.6
Tat 30 μg, 3x 36 3.2 ± 0.5
Tat 30 μg, 5x 34 3.0 ± 0.5
"n indicates the number of individuals evaluable for each parameter according to residual specimen availability, since they were part of second line
laboratory testing".
aStandard deviation; bt-test was applied.
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followed those seen in the CD4+ T cell subsets. In particu-
lar, statistical significant increases of CD8+ naïve and Tcm
cells with a concomitant decrease of the Tem subset were
observed at year 2 and/or year 3 (Figure 7C), whereas, as
reported earlier in treated subjects [46,53], no significant
changes were noticed in OBS subjects (Figure 7D).
Similar results were observed in vaccinees with both
drug regimens (NNRTI/NRTI- or PI-based) for the CD4+
T cell subsets (Figure 8A), whereas for the CD8+ T cell
subsets NNRTI were associated with greater and signifi-
cant decreases of CD8+ Tem and increases of CD8+ Tcm
as compared to PI-based regimens (Figure 8C). In OBS
subjects PI-based regimens had more pronounced effects
on CD4+ and CD8+ T cell subsets, particularly for the
increase of naïve CD4+ T cells (Figure 8B), and for the re-
duction of CD8+ Tem at year 1, whereas NNRTI-based reg-
imens had no effects (Figure 8D). Thus, Tat immunization
restores CD4+ and CD8+ T cell subsets during HAART;
however, differences are seen according to the drug regi-
mens, particularly for the CD8+ T cell subsets which are
better restored with NNRTI-based regimens.
HIV proviral DNA
HIV-1 DNA was evaluated longitudinally up to 3 years
(144 weeks) in vaccinees and OBS subjects prior to orafter stratification by drug regimens. As shown in
Figure 9A, although they had equal baseline mean values
(1.2 log10 copies/μg DNA), a reduction of HIV-1 DNA
was seen in vaccinees as compared to OBS subjects, par-
ticularly under PI-based regimens. When treatment
groups were analyzed separately (Figure 9B), Tat 30 μg,
3x showed the highest, most persistent and statistically
significant HIV-1 DNA reduction with both drug regi-
mens, although a greater decay was observed again with
PI-based regimens. In particular, the percentage of
reduction in all vaccinees under PI-based regimens
(Figure 9A), when statistically significant, ranged from
51% (week 108) to 66% (week 132), and in the Tat 30
μg, 3x group from 52% (week 108) to 65% (week 144)
(Figure 9B).
Since CD4+ T cells harbor most of the provirus detect-
able in blood [46], HIV-1 DNA was then calculated ac-
cording to CD4+ T cell counts. As shown in Figure 10A,
the percentage of proviral reduction in all vaccinees
under PI-based regimens ranged from 26% (week 48) to
60% (week 132), and in the Tat 30 μg, 3x under PI-based
regimens ranged from 53% (week 72) to 85%, (week
144), followed by Tat 7.5 μg, 5x (range from 53% to 67%,
at week 84 and 108, respectively) and Tat 30 μg, 5x
(range from 31% to 47%, at week 96 and 72, respectively)
(Figure 10B). Conversely, lower and transient reductions












n Mean ± s.d.a n Mean ± s.d. n Mean ± s.d. p-valueb p-valueb
Phenotype (cells/μL)
CD4+ 80 694 ± 236 72 624 ± 223 79 700 ± 300 0.8880 0.0755
CD8+ 80 822 ± 344 72 780 ± 443 79 881 ± 360 0.2955 0.1299
B 80 232 ± 111 72 251 ± 132 79 307 ± 164 0.0009 0.0244
NK 80 237 ± 149 72 226 ± 159 79 268 ± 193 0.2596 0.1480
CD4+ subsets (%)
Naïve 21 32 ± 19 73 31 ± 12 31 28 ± 13 0.6337 0.7940
Effectors memory 21 23 ± 14 73 22 ± 12 31 20 ± 8 0.4377 0.6029
Central memory 21 45 ± 15 73 48 ± 9 31 51 ± 9 0.2314 0.3422
CD8+ subsets (%)
Naïve 21 26 ± 11 73 26 ± 12 31 30 ± 11 0.2004 0.0912
Effectors memory 21 53 ± 12 73 52 ± 14 31 47 ± 13 0.0683 0.1174
Central memory 21 20 ± 11 73 22 ± 10 31 23 ± 9 0.4262 0.9136
HIV DNA (log10 copies/10
6
CD4+ cells
78 3.1 ± 0.5 64 3.1 ± 0.5 54 33.0 ± 0.5 0.4505 0.5276
"n indicates the number of individuals evaluable for each parameter according to residual specimen availability, since they were part of second line laboratory
testing". aStandard deviation; bt-test was applied.
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and were mostly observed under PI-based regimens. The
changes of proviral load in OBS recapitulate what previ-
ously reported under successful therapy [59,60].
The longitudinal regression analysis confirmed the
HIV-1 DNA decay in the Tat 30 μg, 3x group, but not in
OBS subjects, with an estimate of 56% reduction after 3
years from vaccination (Figure 11A, B). The decay was
more pronounced under PI-based regimens for whichTable 6 ISS T-002: anti-Tat humoral and cellular immune resp
n Percentage (95%
Anti-Tat humoral responses
Vaccinees 155 79 (73–86)
Tat 7.5 μg, 3x 40 70 (56–84)
Tat 7.5 μg, 5x 40 70 (56–84)
Tat 30 μg, 3x 38 92 (84–100)
Tat 30 μg, 5x 37 86 (75–97)
Anti-Tat cellular responses
Vaccinees 155 84 (79–90)
Tat 7.5 μg, 3x 40 80 (68–92)
Tat 7.5 μg, 5x 40 88 (77–98)
Tat 30 μg, 3x 38 87 (76–98)
Tat 30 μg, 5x 37 84 (72–96)
Comparison among groups
n indicates the number of individuals evaluable for each parameter.
aConfidence interval; bLogistic regression model; cMantel-Haenszel Chi-Square test.the estimate reached over 70% reduction after 3 years,
with a half-life of 88 weeks (Figure 11C).
HIV-1 DNA decay was then analyzed versus anti-Tat
humoral responses adjusted for treatment groups and
antiretroviral therapy by a multivariate regression model
(Table 8). The greatest and most significant HIV-1 DNA
reduction occurred in the presence of both anti-Tat IgM
and IgG Abs at year 2 and, particularly, at year 3 from
vaccination, whereas in the presence of a single anti-Tatonse post-immunization
CIa) Odds ratiob (95% CIa) Odds ratio p-value
reference
1.0 (0.5; 2.2) 1.0000
5.0 (1.8; 13.9) 0.0021
2.7 (1.1; 6.7) 0.0272
reference
1.7 (0.7; 4.4) 0.3253
1.6 (0.6; 4.2) 0.2900
1.3 (0.5; 3.2) 0.5758
0.6697c
Figure 2 Anti-Tat humoral immune response in vaccinees. (A) Percentage of subjects producing Anti-Tat Abs (responders) after Tat immunization
(7.5 μg, 3x n = 40; 7.5 μg, 5x n = 40; 30 μg, 3x n = 38; 30 μg, 5x n = 37). (B) Kaplan-Meier estimates showing the cumulative probability of anti-Tat Ab
durability in responders stratified according to treatment groups and up to week 144 of follow-up (n = 123, median follow-up of 96 weeks).
(C) Percentage of subjects in each treatment group producing anti-Tat IgM (light blue), IgG (red), or IgA (white) Abs. (D) Percentage of
subjects in each treatment group producing two (IgM and IgG, in blue) or three (IgM, IgG and IgA, in red) anti-Tat Ab classes. (E) Anti-Tat IgM (light
blue) and IgA (white) peak titers between 4 and 24 weeks since the first immunization in subjects positive for IgM (7.5 μg, 3x n = 16; 7.5 μg, 5x n = 20;
30 μg, 3x n = 24; 30 μg, 5x n = 23) or IgA anti-Tat Abs (7.5 μg, 3x n = 7; 7.5 μg, 5x n = 9; 30 μg, 3x n = 19; 30 μg, 5x n = 22). (F) Anti-Tat IgG Ab peak
titers between 4 and 24 weeks since the first immunization in subjects positive for IgG anti-Tat Abs (7.5 μg, 3x n = 24; 7.5 μg, 5x n = 24; 30 μg, 3x
n = 32; 30 μg, 5x n = 31). Box plots represent the median, 25th and 75th percentile, with the minimum and maximum values; the outliers are not
represented in the graphs.
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negative vaccinees had a reduction of borderline signifi-
cance at year 3, possibly explained by the fact that most
of these subjects (76%) had Tat-specific cellular re-
sponses. In fact, anti-Tat Ab negative but anti-Tat cellu-
lar positive subjects showed a decrease of HIV-1 DNAboth in year 2 and 3 from vaccination (mean: −0.12 and
−0.16 log10 copies/10
6 CD4+ T cells, representing 24%
and 31% reduction, respectively), whereas a slight in-
crease was detected in subjects with no humoral or cel-
lular responses to Tat (0.1 log10 copies/10
6 CD4+ T cells)
(Table 9). HIV DNA changes similar to those observed
Figure 3 Anti-Tat cellular immune response. IFN-γ, IL-2 or IL-4 production and CD4+ or CD8+ T cell proliferation to Tat in (A) vaccinees or (C)
OBS subjects. The percentages of responders at baseline (white bars) and up to 48 weeks from baseline (blue bars) (vaccinees: IFN-γ, IL-2, or IL-4
n = 151, proliferation n = 140; OBS: IFN-γ, IL-2, or IL-4 n = 60, proliferation n = 54) are shown. Peak intensity of anti-Tat cellular responses in (B)
vaccinees or (D) OBS subjects at baseline (white bars) and up to 48 weeks (blue bars) in responders (subjects with at least one positive response
after baseline) (vaccinees: IFN-γ n = 39, IL-2 n = 38, IL-4 n = 12, CD4+ proliferation n = 86, CD8+ proliferation n = 77; OBS: IFN-γ n = 12, IL-2 n = 11,
IL-4 n = 6, CD4+ proliferation n = 33, CD8+ proliferation n = 34). Box plots represent the median, 25th and 75th percentile, with the minimum and
maximum values; the outliers are not represented in the graphs. The McNemar’s and Wilcoxon signed-rank tests were applied. P-values assess the
values of frequencies and intensity, respectively, up to 48 weeks after immunization versus baseline values.
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subjects according to the presence or absence of Tat-
specific cellular responses (Table 9). Further, the 30 μg,
3x vaccine regimen induced the highest HIV-1 DNA
decay, however, also the 7.5 μg, 5x showed statistically
significant HIV-1 DNA decreases at year 3, whereas the
30 μg, 5x showed a trend only at year 2, whereas no
significant changes were observed in 7.5 μg, 3x group
(Table 8). Finally, Tat vaccination in association with
PI-based regimens resulted again the most effective at
reducing HIV-1 DNA (Table 8).
Neutralization of Tat-mediated Env entry in dendritic cells
Since the Tat 30 μg, 3x regimen was the most effective
at reducing HIV DNA, neutralization of the entry of
oligomeric Env into DC in the presence or absence of
Tat [32] was assessed in this treatment group by analyz-
ing sera at week 0 (baseline) and at week 12, 20 and 48
after immunization. This assay overcomes the problem
posed by HAART interference with neutralization of
HIV-1 infection [61]. Sera blocking Tat-mediated Env
entry in DC by ≥50% versus baseline were indicated asneutralizing. A significant inverse relationship was ob-
served between Tat-mediated Env entry in DC and
anti-Tat Ab binding titers of all isotypes (Figure 12A),
particularly at week 48 (Figure 12B). At this time,
neutralization was observed in 90% of the subjects with
anti-Tat Abs (Figure 12C) and correlated with both
anti-Tat IgM and IgG titers (Figure 12D). Of note, the
presence of anti-Tat Abs and neutralizing activity at
week 48 predicted a significant reduction of HIV-1 DNA,
which was consistently detected at year 2 and particularly
at year 3 (Figure 12E).
Induction of effector memory CD38+ HLA-DR+/CD8+ T
cells and restoration of NK cells
The data described above indicated that proviral reduc-
tion is observed late after immunization, is greatest in
the 30 μg, 3x group, and under PI based regimens, is as-
sociated with the presence of IgM and IgG anti-Tat Abs,
and is predicted by the neutralization of virus entry at
year 1.
In particular, the presence of IgG and IgM anti-Tat
Abs was more frequent in both the 30 μg dose regimens
Ensoli et al. Retrovirology  (2015) 12:33 Page 11 of 28(60% in 30 μg, 3x group and 62% in 30 μg, 5x group)
(Figure 2D), although proviral reduction was greater
when Tat was given 3 times as compared to 5 times.
Therefore, all immunological parameters for which data
were available were compared between the two treatment
groups. As shown in Figure 13 and Figure 14, the only rele-
vant differences were found for CD38+ HLA-DR+/CD8+ T
cell percentage and NK cell number. In particular, in the
30 μg, 3x group, CD38+ HLA-DR+/CD8+ T cells were sig-
nificantly increased at year 1, whereas only a trend was
seen in the 30 μg, 5x group, and thereafter these cells de-
clined in both groups, particularly in the 30 μg, 5x regimen
(Figure 13A). Flow cytometry data analysis indicated that
the increase of CD38+HLA-DR+/CD8+ T cells was due to
the upregulation of HLA-DR expression, a marker associ-
ated with proliferative capacity and found increased in elite
controllers [62]. Stratification of year 1 data by weeks indi-
cated that the increase of this cell phenotype occurred and
was significant in both groups after 3 immunizations (week
12) (Figure 13C), whereas further immunizations in the 30
μg, 5x group did not increase or maintain these cells,
which, in contrast, were reduced down to undetectable
levels at 48 weeks (Figure 13C). Significant reductions were
observed in OBS subjects upon time (Figure 13B).
Concerning NK cells, the 30 μg, 3x group showed
significant increases at year 2, whereas not significant in-
creases were seen in the 30 μg, 5x group (Figure 14A),
and few or no changes were observed in OBS subjects
(Figure 14B).Table 7 Adverse events occurred up to week 48 in the ISS T-0
Treatment groups
Tat 7.5 μg, 3x
N %
Number of subjects in the safety population 43
Number of subjects with at least one adverse event 27 62.8
Serious adverse events 2 7.14
Non-Serious Adverse Events 26 92.9
Adverse Events leading to withdrawal 1 1.3
Deaths 0









Severe 2 5.9Thus, the 30 μg, 3x regimen had the highest frequency
of effector cells (CD38+HLA-DR+/CD8+ and NK cells),
endowed with killing capacity against virus-infected cells
[62]. Of note the CD38+ HLA-DR+ CD8+ T cells are ef-
fector memory CD8+ T cells found to be increased in
elite controllers [62].
Discussion
Several strategies have been undertaken to intensify
HAART efficacy in order to attack the virus reservoirs,
reduce immune activation and to restore functional T, B
and NK cells [9]. However, they have been unsuccessful
or have had only a marginal effect [9,63].
The results of the ISS T-002 reported here not only
confirm previous findings of safety and immunogenicity
of the Tat vaccine [22,26-28], but also show that
immunization with Tat in HAART-treated, virologically-
suppressed subjects increases T, B and NK cell numbers
and promotes restoration of CD4+ and CD8+ functional
T cell subsets toward homeostasis. This is not observed
in the external reference group, which recapitulates what
is reported in the literature after years of HAART [1].
Immune restoration started early after vaccination, in-
creased upon time and was durable (up to 3 years). In
particular, a mean increase of CD4+ T cells up to values
of about 100 cells/μl was observed in vaccinees at year 3
(Figure 4A), which appears highly meaningful in subjects
with a mean of 6 years of therapy. In fact, a successful
HAART regimen is expected to induce increments of02 study
Tat 7.5 μg, 5x Tat 30 μg, 3x Tat 30 μg, 5x
N % N % N % Total
44 40 41 168
26 59.1 26 65.0 25 61.0 103
2 7.1 3 11.1 3 11.1 10
26 92.9 24 88.9 24 88.9 100
2 2.5 2 2.6 2 2.9 7
0 0 0 0
3 8.6 4 12.5 8 23.5 18
5 14.3 3 4.0 3 8.8 12
3 8.6 4 12.5 2 5.9 13
3 8.6 1 3.3 0 0.0 6
21 60.0 20 62.5 21 61.8 87
25 67.6 22 71.0 21 63.6 94
8 21.6 7 22.6 9 27.3 30
4 10.8 2 6.4 3 9.1 11
Figure 4 (See legend on next page.)
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Figure 4 CD4+, CD8+, B and NK cell numbers. Changes from baseline of (A, B) CD4+, (C, D) CD8+, (E, F) B and (G, H) NK cells at years 1, 2
and 3 in vaccinees (left panels) (n = 152 at year 1 ; n = 114 at year 2 ; n = 69 at year 3) and in OBS subjects (right panels) (n = 79 at year 1 ; n = 42
at year 2 ; n = 30 at year 3), respectively. Data are presented as mean values with standard error. A longitudinal analysis for repeated measurements
was applied. P-values assess the values at year 1, 2 or 3 after immunization versus baseline values.
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since therapy initiation and then of approximately 50 cells/
year in the next 3 years or so. Then CD4+ T cells plateau,
remaining generally stable thereafter [51-53] as observed in
OBS subjects (Figure 4B). Further, in vaccinees CD4+ T cell
number increased progressively independently from the
nadir (Figure 6A). This is of clinical relevance since it is
known that subjects with a nadir ≤250 cells/μl do not
respond as well to therapy [52,53].
Taken together these immunological changes appear con-
sistent with a restoration of immune functions, well beyond
what is achieved upon cART, in which, for example, CD4+ T
cell counts are incompletely restored, and CD4+ and CD8+
central memory subsets remain underrepresented, due to the
residual immune activation which fuels the transition from
naive to effector cells and hampers the transition to the cen-
tral memory phenotype generally occurring in the contrac-
tion phase of an immune response (reviewed in [64,65]). In
this regard the increase of central memory CD4+ T cells and
the reduction of effector memory CD8+ T cells in association
with the expansion of central memory CD8+ T cells appear
of particular relevance (Figure 7).
Concerning other therapeutic approaches including HIV
vaccines tested so far in humans (reviewed in [66-68]), it
should be underscored that in most vaccine trials therapy
was interrupted to assess the potency of the immunological
control of infection provided by vaccination, and these stud-
ies were not aimed at evaluating the immunological recovery
with the exclusion of the CD4+ T cell counts, which, how-
ever, do not appear to go beyond the restoration provided by
cARTalone (reviewed in [67,68]).
In this contest of T cell immune restoration, an increase of
B (Figure 4 E, F) and NK cells (Figure 4 G,H) was detected in
vaccinees after a mean of 6 years of therapy. This was not ob-
served in OBS subjects and it is not achieved with other thera-
peutic approaches [57,58]. Of note, B cell numbers at baseline
were significantly lower in vaccinees as compared to OBS sub-
jects, although well within the normal range in both groups.
However, opposite kinetics were observed upon time in the
two groups, with vaccinees experiencing a moderate (about
30–40 cell/μL) but durable (3 years) and statistical significant
(with respect to the baseline levels) expansion of the absolute
B cell counts, whereas an opposite, non-significant, trend was
observed in OBS subjects over the two years of follow up.
This difference with respect to the baseline levels recorded
for the T-002 trial would argue against a simple leveling
off of total B cell counts, eventually leading to comparable
absolute counts in the two studies at the end of follow-up.Although Tat immunization promoted similar effects
with both drug regimens, NNRTI-based regimens were
the most effective at restoring CD8+ T cell subsets.
Overall, all treatment groups experienced, although to
a different extent, immune restoration with the 7.5 μg,
3x performing the least.
Immune restoration was followed by a significant and
progressive HIV-1 DNA decay in blood, particularly with
Tat 30 μg, 3x under PI-based regimens, which was associ-
ated with the presence of both anti-Tat IgM and IgG Abs
and Env neutralization, that predicted HIV-1 DNA decay.
In addition, only the 30 μg, 3x group showed significant
increases of effector memory CD38+ HLA-DR+/CD8+ T
cells and NK cells, which are known to exert killing activ-
ities against virus infected cells (reviewed in [69,70]). In
particular, significant increases of CD38+ HLA-DR+/CD8+
T cells were observed in both 30 μg regimens after 3 im-
munizations and were associated with peak IgM and IgG
anti-Tat Ab titers. However, additional immunizations in
the 30 μg, 5x group did not increase or maintain but, in
contrast, further reduced this cell phenotype, supporting
the concept that too many vaccine inocula may initiate
suppressive regulatory mechanisms likely by overstimula-
tion of the immune system [71,72].
The risk to hamper a good antiviral response by im-
mune overstimulation is particularly true for Tat, which
is an active molecule, capable of targeting and entering
efficiently key antigen-presenting cells (i.e. DC), inducing
cell activation and maturation [24,42]. In addition, since
the vaccine is administered intradermally and the derma
is very rich in DC, higher doses and/or repeated immuni-
zations may easily induce an overstimulation, modifying
vaccine-induced immune responses [73,74]. Thus, the 30
μg, 3x regimen appears to be the best one to achieve both
immune restoration and antiviral responses.
All the analyses shown herein were performed in the
immunogenicity population as defined in the clinical
protocol, however, data (anti-Tat Abs, CD4+ T cells and
HIV proviral DNA) did not change by utilizing an
“intention-to-treat” analysis.
Taken together, these data indicate that Tat
immunization induces key antiviral activities likely due
to multiple mechanisms. In particular, anti-Tat Abs can
block the Tat/Env complex formation and virus entry
into DC and other integrin-expressing cells of the
reticular-endothelial system [32]. These cells represent
the first HIV-1 targets at the portals of entry in pri-
mary infection [75,76], and become HAART-resistant
Figure 5 (See legend on next page.)
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Figure 5 CD4+, CD8+, B and NK cell numbers stratified by antiretroviral regimens. Changes from baseline of (A, B) CD4+, (C, D) CD8+,
(E, F) B and (G, H) NK cells at years 1, 2 and 3 according to antiretroviral regimens in vaccinees (left panels) (NNRTI- or NRTI-based n = 104 at year
1 ; n = 80 at year 2 ; n = 49 at year 3; PI-based n = 48 at year 1 ; n = 34 at year 2 ; n = 20 at year 3) and OBS subjects (right panels) (NNRTI- or
NRTI-based n = 49 at year 1 ; n = 21 at year 2 ; n = 14 at year 3; PI-based n = 30 at year 1 ; n = 20 at year 2 ; n = 16 at year 3). Data are presented
as mean values with standard error. A longitudinal analysis for repeated measurements was applied. P-values assess the values at year 1, 2 or 3
after immunization versus baseline values, both overall and stratified by drug regimens (NNRTI/NRTI- or PI-based).
Ensoli et al. Retrovirology  (2015) 12:33 Page 15 of 28virus reservoirs in chronic infection [1-3,77-79]. Since
HIV-1 sera regain neutralizing activity in the presence
of anti-Tat Abs, it is likely that these Abs block the on-
going cell-to-cell virus transmission [6], thus impeding
replenishment of the virus reservoir. This then pro-
gressively reduces owing to the turnover of infected
CD4+ T cells [48,80], as suggested by the late proviral
decay and its kinetics. In this regard, the restoration of
functional T cell subsets and NK cells seen early after
Tat vaccination may render more effective immuneFigure 6 CD4+ T cells stratified by CD4+ nadir and CD4+/CD8+ T cell r
T cell ratio at years 1, 2 and 3 in vaccinees (left panels) (n = 152 at year 1 ; n =
(n = 79 at year 1 ; n = 42 at year 2 ; n = 30 at year 3), respectively. Vaccinees w
subjects with CD4+ T cell nadir ≤250 cells/μl: n = 45 ; >250 cells/μl n = 34. Da
analysis for repeated measurements was applied. P-values assess the values arecognition and clearance of infected cells [48], effectively
contributing to proviral DNA decay. In particular, the in-
duction of both CD38+ HLA-DR+/CD8+ T cells, which
have been demonstrated to exert effective cytotoxic anti-
viral activity in elite controllers [62], and NK cells suggest
that these effector cells may contribute to proviral reduc-
tion. However, at present a formal proof of the killing
activity of these cells in vaccinees is not available.
A limitation of this study is that it was not a double-
blinded, placebo-controlled trial. However, this decisionatio. Changes from baseline of (A) CD4+ by CD4+ nadir and (B) CD4+/CD8+
114 at year 2 ; n = 69 at year 3) and in OBS subjects (right panels)
ith CD4+ T cell nadir ≤250 cells/μl: n = 32, >250 cells/μl n = 120; OBS
ta are presented as mean values with standard error. A longitudinal
t year 1, 2 or 3 after immunization versus baseline values.
Figure 7 Naïve, central and effector memory CD4+ and CD8+ T cells. Changes from baseline of naïve, Tem and Tcm (A, B) CD4+ and (C, D)
CD8+ T cell percentage at years 1, 2 and 3 for vaccinees (left panels) (n = 94 at year 1 ; n = 75 at year 2 ; n = 32 at year 3) and OBS subjects
(right panels) (n = 32 at year 1 ; n = 20 at year 2). Data are presented as mean values with standard error. A longitudinal analysis for repeated
measurements was applied. P-values assess the values at year 1, 2 or 3 after immunization versus baseline values.
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the effect of Tat vaccination on biomarkers of disease,
with the aim of including additional analyses if deemed
necessary to better understand mechanism(s) of action
and to define the proper biomarkers for future trials. To
this goal an external reference group (OBS) was used
following the recommendations of regulatory guidelines
[50]. This group was not used as a control of the pre-
specified endpoints of the protocol (immunogenicity/
safety) but served only to provide a side-by-side view of
the immunological and virological disease biomarkers in
anti-Tat Ab negative subjects after years of effective
HAART without any direct comparison with the trial
subjects, since they belong to two separate studies.
Indeed, in the OBS subjects the results for all the im-
munological and virological parameters analyzed are
consistent with those reported in the literature in suc-
cessfully treated patients after years of HAART [1].
The open label design of the trial permitted to verify
the rapid achievement of the study primary and sec-
ondary endpoints and to appreciate the immune re-
constitution induced by vaccination [22]. This allowedthe implementation of the study protocol with proper
amendments, such as inclusion of more immune compro-
mised patients who, in fact, showed the most pronounced
immunological benefit. Of note, this approach also
allowed the design and the definition of the proper la-
boratory testing of a placebo-controlled double-blinded
confirmatory phase II study of the Tat vaccine at 30 μg,
3x (ISS T-003, Clinicaltrials.gov NCT01513135), which
has been successfully completed in 200 individuals on
effective HAART in South Africa.
Conclusions
The results indicate that the Tat vaccine candidate is
safe and immunogenic. In addition, they suggest that
Tat-induced immune responses are necessary to restore
immune homeostasis and effective antiviral activities.
However, results from the trial just completed in South
Africa and further efficacy studies will be needed to
confirm these findings as well as to address issues of
HIV subtype variability, and other problems of virus
variability, to prove vaccine efficacy in other HIV clade
infections. Therefore, at this time, no definitive conclusions
Figure 8 Naïve, central and effector memory CD4+ and CD8+ T cells stratified by antiretroviral regimens. Changes from baseline of naïve,
Tem and Tcm (A, B) CD4+ and (C, D) CD8+ T-cell percentage at years 1, 2 and 3 according to antiretroviral regimens in vaccinees (left panels)
(NNRTI- or NRTI-based n = 59 at year 1 ; n = 49 at year 2 ; n = 21 at year 3; PI-based n = 35 at year 1 ; n = 26 at year 2 ; n = 11 at year 3) and
OBS subjects (right panels) (NNRTI- or NRTI-based n = 19 at year 1 ; n = 9 at year 2; PI-based n = 13 at year 1 ; n = 11 at year 2). Data are presented as
mean values with standard error. A longitudinal analysis for repeated measurements was applied. P-values assess the values at year 1, 2 or 3 after
immunization versus baseline values, both overall and stratified by drug regimens (NNRTI/NRTI- or PI-based).
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cine approach, which has been considered controversial
by other groups. Nevertheless, the findings in this study
may help establishing key parameters for HAART intensi-
fication and a functional cure.
Methods
Study design and participants
The phase II therapeutic trial with the biologically ac-
tive HIV-1 Tat protein (ISS T-002) was a multicenter,
randomized, open label trial (ISS T-002, Clinicaltrials.
gov NCT00751595) designed to evaluate immunogen-
icity and safety, and to explore immunological and
virological biomarkers of disease (second-line testing).
Tat was administered at 7.5 μg or 30 μg, given 3 (3x) or
5 (5x) times to 168 HIV-1 infected HAART-treated
adults, anti-Tat Ab negative at baseline with undetect-
able levels of plasma viremia (<50 copies/mL) in thelast 6 months prior to enrollment, and CD4+ T-cell
number ≥200 cells/μL. The trial was closed at week 48
after the first immunization and a subgroup of patients
was followed up to 3 years (n = 76 up to 96 weeks and
n = 45 up to 144 weeks). A group of 79 anti-Tat Ab
negative HAART-treated subjects from a parallel ob-
servational (OBS) study (ISS OBS T-002, Clinicaltrials.
gov NCT01024556) represented the external reference
group for disease biomarkers according to ICH guide-
lines [50]. In particular, the potential bias of an external
nonrandomized control group was limited according to
recommendations of the regulatory guidelines by enrolling
subjects in the same clinical centers, with the same in-
clusion criteria of the trial, by using the same proce-
dures, and by simultaneous evaluations by the same
core laboratory. This group recapitulates what is usu-
ally observed in individuals after years of effective
HAART [1-7,46,51-58].
Figure 9 Blood HIV-1 DNA load (expressed as log10 copies/μg DNA) stratified by antiretroviral regimens. (A) Changes of HIV-1 DNA
(expressed as log10 copies/μg DNA) versus baseline according to antiretroviral regimens in vaccinees (NNRTI- or NRTI-based n = 102; PI-based
n = 45) or OBS subjects (NNRTI- or NRTI-based n = 36; PI-based n = 26). (B) Changes of HIV-1 DNA versus baseline in vaccinees of each treatment
group stratified according to ARV regimens (7.5 μg, 3x n = 38; 7.5 μg, 5x n = 37; 30 μg, 3x n = 37; 30 μg, 5x n = 35). The dotted lines represent the
99% confidence interval of HIV-1 DNA mean change from baseline (−0.21, 0.04 log10 copies/μg) in OBS subjects (all time points). In all panels data
are presented as mean values with standard error. Median time of follow-up was 96 weeks for vaccinees and 120 weeks for OBS subjects. A longitudinal
analysis for repeated measurements was applied. P-values assess the values at each week after immunization versus baseline values stratified by drug
regimens (NNRTI/NRTI- or PI-based).
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The primary outcome of the study (immunogenicity)
was measured by the induction, magnitude and persist-
ence of the humoral immune responses to Tat. Cellular
immune responses to Tat were a co-primary endpoint.
The anti-Tat humoral immune response was evaluated
by determination and titration of IgM, IgG and IgA anti-
Tat Abs in sera. The anti-Tat cellular immune response
was measured in blood by the assessment of CD4+ and
CD8+ lymphoproliferative responses, and production of
IFN-γ, IL-4 and IL-2 in response to Tat, as detailed
below.
The secondary outcome of the study (safety) was
assessed by the collection of all adverse events occurred
during the trial, including vital signs monitoring, andany clinically significant change in hematological, bio-
chemical and coagulation parameters. The study was
completed at 48 weeks according to a protocol amend-
ment approved by Ethic Committees (see below), vacci-
nees were followed up until the last enrolled subjects
reached the 48 weeks. Therefore, the safety results are
shown up to study closure (48 weeks), but also described
for the entire follow-up (144 weeks). All randomized
subjects who received at least one administration of the
vaccine (168 subjects) were included in the safety data
analysis. All AE were classified according to the pre-
ferred term and the system organ class (SOC) of the
Medical Dictionary for Regulatory Activities (MedDRA)
as well as on the basis of the drug relationship and grade
of severity. Safety data were periodically evaluated during
Figure 10 Blood HIV-1 DNA load (expressed as log10 copies/10
6 CD4+ T cells) stratified by antiretroviral regimens. (A) Changes of HIV-1
DNA (expressed as log10 copies/10
6 CD4+ T cells) in vaccinees (NNRTI- or NRTI-based n = 97; PI-based n = 45) or OBS subjects (NNRTI- or NRTI-based
n = 30; PI-based n = 24). (B) Changes of HIV-1 DNA in vaccinees of each treatment group stratified according to ARV regimens (7.5 μg, 3x n = 36;
7.5 μg, 5x n = 36; 30 μg, 3x n = 36; 30 μg, 5x n = 34). The dotted lines represent the 99% confidence interval of HIV-1 DNA mean change from baseline
(−0.24, 0.02 log10 copies/10
6 CD4+ T cells) in OBS subjects (all time points). In all panels data are presented as mean values with standard error. Median
time of follow-up was 96 weeks for vaccinees and 120 weeks for OBS subjects. A longitudinal analysis for repeated measurements was applied.
P-values assess the values at each week after immunization versus baseline values stratified by drug regimens (NNRTI/NRTI- or PI-based).
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were submitted to the Competent Authorities, according
to the current regulatory requirements.
Sample size and randomization
As the primary objective of the study protocol was the
immunogenicity of the Tat vaccine, sample size was esti-
mated separately in each vaccination arm. To observe a
proportion of subjects with a humoral immune response
to vaccination (primary endpoint) within at least
75%-80%, considering a margin of error of 12%-13%
and a confidence level of 95%, at least 40 evaluable
subjects per treatment group were required. In addition,
this sample size was sufficient to detect as statisticallysignificant a difference of 0.5 log10 in the peak of anti-Tat
antibodies among the immunization groups, assuming a
maximum common standard deviation of 0.8 log10, with a
significance level of 5% and a power of 80%. Sample size
was calculated using nQuery Advisor® software, version
7.0.
Subjects were randomized into 4 treatment groups to
ensure unbiased patients allocation as described earlier
[22]. The Randomization list was generated by the
appointed Contract Research Organization (CRO) using
a block size of 4, according to a randomization scheme
of 1:1:1:1 (RND PLUS 2.10 software). The randomization
assignment was carried out by the CRO via web once
eligibility was established by the clinical staff. The
Figure 11 HIV-1 DNA decay in individuals immunized with Tat at 30 μg, 3x or OBS subjects. (A) Longitudinal regression analysis of HIV-1
DNA (log10 copies/10
6 CD4+ T cells) using a random-effect regression model up to 144 weeks since the first immunization in vaccinees (Tat 30 μg, 3x,
n = 37) or OBS subjects (n = 62). All longitudinal data were included in the analysis with a median of 108 weeks of follow-up in vaccinees and 120
weeks in OBS subjects, respectively. (B) Estimates of HIV-1 DNA decay based on the regression model after 1, 2 and 3 years since the first immunization
in vaccinees (Tat 30 μg, 3x in red) and in OBS subjects (in blue). (C) Estimates of HIV-1 DNA annual decay in vaccinees immunized with Tat 30 μg, 3x
stratified according to NNRTI- or NRTI-based (in blue, n = 25) or PI-based (in red, n = 12) regimens. Results in panels B and C are expressed as the
percentage of HIV-1 DNA decay with 95% confidence interval (CI).
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provided via web within the block’s numbers that the
clinical site had received [22].
Clinical study protocol and amendments
The clinical study protocol “A phase II randomized,
open label, immunogenicity and safety trial of the vac-
cine based on the recombinant biologically active HIV-1
Tat protein in anti-Tat negative HIV-1 infected HAART-
treated adult subjects” (dated 12/02/2008), submitted
and approved by national competent authorities, included
128 individuals with chronically suppressed plasma
viremia (viral load <50 copies/ml in the last 6 months
prior to the screening) without a history of virologic re-
bound, CD4+ T cell counts ≥400 cells/μl, pre-HAART
CD4+ nadir >250 cells/μl (Table 10).
An interim analysis performed at 48 weeks in 87 sub-
jects whom completed the treatment phase [22] indi-
cated that the Tat vaccine candidate did not raise any
safety concern, therefore, after approval by the DSMB,
the study was amended (clinical study protocol dated24/11/2009) to include subjects with less restrictive in-
clusion/exclusion criteria (history of virologic rebound,
CD4+ T cell counts ≥200 cells/μl irrespective of pre-
HAART CD4+ nadir, history of AIDS-related opportun-
istic or neoplastic disease, HBV or HCV co-infections),
and to increase the total number of subjects from 128 to
160, upon recalculation of the sample size. Moreover,
the follow-up period of the volunteers was extended for
additional two years (from 48 to 144 weeks) to evaluate
the persistence of the anti-Tat humoral and cellular im-
mune responses (Table 10).
A further amendment (dated 20/07/2012) was submit-
ted and approved by the Ethics Committees to close the
study at 48 weeks of follow-up (Table 10). This was re-
quired to initiate an “ad hoc” observational study of
follow-up, which was further extended until week 180
from the first immunization given the promising results
on disease biomarkers, and to render the study more
cost-effective. Volunteers were therefore invited to enter
the ISS T-002 Extended Follow-up study (ClinicalTrials.
gov NCT02118168), which is currently ongoing.
Table 8 HIV-1 DNA vs anti-Tat humoral immune responses, adjusted for treatment groups and antiretroviral drug
regimens
HIV-1 DNA (log10 copies/10
6 CD4+) Year(a) Estimate(b) 95% CI(c) p value
Anti-Tat humoral response
IgM+ and IgG+ 2nd −0.17 −0.28; −0.05 0.0036
3rd −0.26 −0.41; −0.10 0.0012
IgM+, IgG+ or IgA+ 2nd 0.02 −0.08; 0.12 0.3837
3rd −0.17 −0.32; −0.01 0.0356
Ab Negative 2nd −0.13 −0.30; 0.04 0.1345
3rd −0.23 −0.46; −0.00 0.0546
Treatment groups
Tat 7.5 μg, 3x 2nd −0.01 −0.14; 0.12 0.8997
3rd 0.03 −0.18; 0.25 0.7572
Tat 7.5 μg, 5x 2nd −0.10 −0.17; 0.03 0.1794
3rd −0.25 −0.43; −0.10 0.0057
Tat 30 μg, 3x 2nd −0.16 −0.35; 0.03 0.0975
3rd −0.53 −0.73; −0.33 <0.0001
Tat 30 μg, 5x 2nd −0.13 −0.29; 0.02 0.0887
3rd −0.12 −0.31; 0.07 0.2156
Tat 30 μg, 3x vs Tat 7.5 μg, 3x 3rd −0.56 −1.02; −0.10 0.0050
Antiretroviral regimens
NNRTI-based or NRTI −0.05 −0.16; 0.05 0.2971
PI-based −0.25 −0.36; −0.15 <0.0001
NNRTI-based or NRTI vs PI-based 0.20 0.06; 0.34 0.0047
(a)Year since first immunization: 48, 72, 84, 96 weeks (2nd year); 108, 120, 132, 144 weeks (3rd year); (b)Least square means; (c)confidence interval.
Multivariate analysis of variance for repeated measures of longitudinal samples from 136 individuals.
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to the pre-amendments clinical study protocol, while the
present manuscript reports the 48-week data from the
post-amendment, completed trial and the results from a
subgroup of study participants for whom a longer follow-
up was available (n = 76 up to 96 weeks and n = 45 up to
144 weeks).
Measurements of anti-Tat antibodies and cellular
responses
Anti-Tat Abs were assessed by ELISA as described
[22,40,81]. Ab titers equal or higher than 25 for IgM
and IgA, or 100 for IgG were considered positive.
IFN-γ, IL-2 and IL-4 ELIspot were performed as de-
scribed [22]. IFN-γ ELIspot was considered positive
when spot-forming cells (SFC)/106 cells were ≥30, and
fold-increase over control was ≥3. The IL-2 and IL-4
ELIspot were considered positive when fold-increase
was ≥3.
T-cell proliferation was assessed by CFSE and
expressed as fold-increase, calculated as the ratio of pro-
liferation index with Tat versus controls, and considered
positive when ≥2, as described [22].Lymphocyte phenotyping
Peripheral blood lymphocytes were phenotyped with the
BD Multitest 6-color TBNK reagent with BD Truecount
tubes (BD Biosciences, San Jose, CA, USA). Samples
were acquired with a FACSCanto flow cytometer (BD
Biosciences) and data analyzed with a dedicated software
(FACSCanto Clinical Software, BD Biosciences), as
described [22].
For naïve, central and effector memory CD4+ or CD8+ T
cell subsets, peripheral blood mononuclear cells were
stained with anti-human CD3+ (PerCP), CD8+ (APC),
CD45RA (FITC), CD62L (PE) monoclonal Abs (MultiT-
EST™ BD Biosciences) and anti-human CD4+ (APC-Cy7)
Ab (BD Biosciences), acquired by FACSCanto flow cyt-
ometer and analyzed with the BD FACSDiva Software (BD
Biosciences) as described [22].
T cell subsets were identified by hierarchical gating
(morphological, on CD3+, and then on CD4+ or CD8+ T
cells). Collective quadrant gates based on CD45RA and
CD62L expression on CD3+/CD4+ or CD3+/CD8+ T
cells identified naïve (CD45RA+/CD62L+), central
memory (Tcm) (CD45RA−/CD62L+), effector memory
(Tem) (CD45RA−/CD62L− and CD45RA+/CD62L−)
Table 9 Anti-Tat cellular response according to anti-Tat
Abs and HIV-1 DNA vs anti-Tat immune responses
n/N(b) Percentage
Anti-Tat cellular response in vaccinees(a)
IgM+ and IgG+ 60/67 89.5
IgM+, IgG+ or IgA+ 34/40 85.0
Ab Negative 22/29 75.9
HIV-1 DNA (log10 copies/10
6
CD4+ T cells)
Year(c) Mean ± s.e.(d) n
Vaccinees
Anti-Tat Ab negative and cellular
positive
2nd −0.08 ± 0.09 21
3rd −0.21 ± 0.11 11
2nd and 3rd −0.08 ± 0.08 22
Anti-Tat Ab negative and cellular
negative
2nd 0.09 ± 0.14 7
3rd 0.10 ± 0.57 3
2nd and 3rd 0.06 ± 0.17 7
OBS subjects(e)
Anti-Tat Ab negative and cellular
positive
2nd −0.12 ± 0.07 37
3rd −0.16 ± 0.07(*) 28
2nd and 3rd −0.13 ± 0.07 37
Anti-Tat Ab negative and cellular
negative
2nd −0.07 ± 0.07 8
3rd 0.09 ± 0.12 8
2nd and 3rd 0.00 ± 0.05 8
(a)Cumulative anti-Tat cellular responses up to 48 weeks in vaccinees. Anti-Tat
cellular responses included IFN-γ, IL-4, and IL-2 production and CD4+ or CD8+
T cell proliferative responses.
(b)n = number of subjects positive for anti-Tat cellular responses; N = total
number of evaluated subjects. (c)Year since first immunization: 48, 72, 84, 96 weeks
(2nd year); 108, 120, 132, 144 weeks (3rd year). (d)s.e. = standard error; (*) p = 0.0426,
Student’s t-test for paired data. (e)The frequency of anti-Tat cellular responses in OBS
subjects was 45/61 (74%).
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CD3+/CD4+ or CD3+/CD8+ T cells.
To evaluate the expression of CD38 and HLA-DR on
CD8+ T cells, whole blood was stained with anti-CD8
FITC/CD38 PE/CD3 PerCP/HLA-DR APC (MultiTEST™
BD Biosciences). Collective quadrant gates based on
HLA-DR and CD38 expression on CD8+ T cells were
established.
Neutralization of Tat-mediated trimeric Env entry in
monocyte-derived dendritic cells by sera
Monocyte-derived DC from healthy donors were cul-
tured and induced to maturation as described [24,32].Purity of DC was always ≥99%. Tat-mediated Env entry
in monocyte-derived DC was assessed as described [32].
Briefly, sera were diluted 1:30 in phosphate buffered sa-
line and incubated for 60 min at 37°C with trimeric Env
(0.4 μM) previously premixed for 10 min at 25°C with
Tat (0.4 μM) or degassed PBS (control). Samples were
then added to DC (2×105 cells/mL) to a 1:5 final dilution
and incubated for 10 min at 37°C. Cells were then washed
with cold medium and treated for 10 min at 37°C with
trypsin-ethylenediaminetetraacetic acid (Life Technolo-
gies, Paisley, UK) to remove any externally bound protein.
After fixation and permeabilization, DC were stained with
rabbit anti-gp120 polyclonal Abs (Chem Progress, Milan,
Italy) or purified rabbit IgG control Abs (Sigma-Aldrich,
Milan, Italy), followed by FITC-conjugated anti-rabbit Ig
(Pierce, Rockford, IL, US). Fluorescence was analyzed by
flow cytometry, and results expressed as the percentage of
Env positive cells as compared to isotype stained samples.
A pool of sera from six healthy donors and a monoclonal
Ab against Tat (mAb 2A4.1, obtained from the AIDS Re-
search and Reference Reagent Program, Division of AIDS,
NIAID, NIH) were used as negative and positive controls,
respectively.
Quantification of HIV-1 DNA by real-time PCR
HIV-1 DNA quantification was performed by SYBR
green real-time polymerase chain reaction (PCR), as de-
scribed [82,83]. DNA was obtained from 1.6 mL of per-
ipheral blood. After incubation for 45 min at 37°C in a
lysis buffer (sodium dodecyl sulfate 5%, 8M Urea, 0.3M
NaCl, 10 mM Tris–HCl pH 7.5, 10 mM EDTA pH 8.0),
DNA was purified by phenol extraction followed by
ethanol precipitation and RNase treatment, and amount
and quality evaluated with a NanoDrop ND-1000 Spectro-
photometer by assessing the ratio of absorbance at 260
nm and 280 nm (NanoDrop Technologies, Wilmington,
DE, US). Real-time PCR was performed using the HIV-1
DNA quantitative PCR kit (Diatheva s.r.l., Fano, Italy),
on a 7700 Real-Time PCR System (Applied Biosystems,
Foster City, CA, US). Each sample was analysed in trip-
licate. Forward and reverse primers (5’- TAGCAGT
GGCGCCCGA -3’ and 5’- TCTCTCTCCTTCTAGCC
TCCGC -3’, respectively) were designed to amplify a
161 bp fragment derived from the 5’ long terminal re-
peat (LTR) U5 end to Gag-Pol start sequence of HIV-1
(GenBank accession no. AF003888). Primers’ specificity
for HIV-1 group M has been previously confirmed both in
silico using BLAST (http://www.hiv.lanl.gov/content/
sequence/HIV/COMPENDIUM/2012compendium.htmL),
and by real-time PCR with different HIV-1 subtypes
(B, C, F, CRF 01_AE and CRF 02_AG), the reference
strains A, D, H, and the complete DNA sequence of
HIV-2 ROD (EU Programme EVA Centralised Facility for
AIDS Reagents, NIBSC, UK) [83]. The cross-reaction with
Figure 12 Neutralization of Tat-mediated Env entry in DC and HIV-1 DNA in vaccinees. (A) Relationship between Tat-mediated entry of
trimeric Env in DC and anti-Tat IgM (blue), IgG (red) and IgA (violet) Ab binding titers in subjects immunized with Tat 30 μg, 3x (generalized
estimating equations with adjustment for repeated measures in the same patient; longitudinal samples from 31 individuals). (B) Percentage of
Env entry in DC in the presence or absence of Tat in subjects immunized with Tat 30 μg, 3x at 48 weeks since the first immunization (n = 32)
(Student’s t-test). Data are expressed as mean changes from baseline with standard error. (C) Inhibition of Tat-mediated Env entry in DC by anti-Tat Ab
positive (n = 20) and anti-Tat Ab negative (n = 12) sera at week 48 from subjects immunized with Tat 30 μg, 3x. Of the 32 subjects evaluated, 30 were
positive for anti-Tat Abs before week 48. Data are expressed as the percentage of subjects showing neutralization of Tat-mediated Env entry at 48
weeks as compared to baseline. (Fisher's Exact test) (D) Pearson correlation between anti-Tat IgM and IgG Ab titers at 48 weeks and Tat-mediated Env
entry in DC at 48 weeks versus baseline in subjects immunized with Tat 30 μg, 3x (n = 32). (E) Reduction from baseline of HIV-1 DNA (log10 copies/106
CD4+ T cells) over time in sera from vaccinees (Tat 30 μg, 3x) positive for neutralization (≥50%) of Env entry in DC at week 48 since vaccination
(n = 20). Data in panels are presented as mean values with standard error. Changes from baseline of HIV-1 DNA in subjects with anti-Tat Abs and
neutralizing activity were evaluated with a longitudinal analysis for repeated measurements. P-values assess the values at each week after immunization
versus values at baseline.
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testing 150 HIV-1 negative blood donors [83]. HIV-1
DNA copy number was estimated by interpolation of the
Ct (threshold cycle), determined on a standard curve with
a 10-fold serial dilutions (105 to 101), and 2 copies dilu-
tions of a plasmid containing the 161 bp HIV target re-
gion, including the Primer Binding Sites (PBS plasmid), as
described [83]. The standard curve was considered valid
when the slope was between −3.50 and −3.32 (93-100% ef-
ficiency) and the minimum value of the coefficient of cor-
relation (R2) was 0.98. The limit of quantification was 2
copies per μg of DNA, with a detection limit of 1 copy
and a dynamic range of quantification of 5 orders of mag-
nitude (105 to 101). The reproducibility, assessed by calcu-
lating the mean coefficient of variation (CV%) for the Ct
values, was determined as 1.4%, confirming quantification
in the dynamic range. Results were expressed as log10
copies/μg DNA or as log10 copies/10
6 CD4+ T cells. Inthe latter case, it was calculated as the ratio between
copies/μg DNA and CD4+ T cell number present in
1.5× 105 white blood cells (WBC): [(copies/μg DNA)/
(CD4+/WBC) × 150,000 WBC] × 106.
Statistical analysis
Two populations were considered for the statistical ana-
lyses: the immunogenicity population (155 subjects),
representing all randomized individuals who received at
least 3 immunizations (excluding also two subjects with
poor ARV compliance), and the safety population (168
subjects), representing all randomized subjects who re-
ceived at least one administration of the vaccine. An
“intention-to-treat” analysis was also applied to anti-Tat
Abs (n = 168), CD4+ T cell number (n = 159) and pro-
viral DNA (n = 150). Since the assessment of lymphocyte
subsets and proviral DNA was included in the study
second-line laboratory testing, they were performed
Figure 13 CD38+HLA-DR+/CD8+ T cells in individuals immunized with Tat at the 30 μg doses or in OBS subjects. Changes from baseline
of CD38+HLA-DR+/CD8+ at years 1, 2 and 3 in (A) vaccinees of the Tat 30 μg, 3x group (year 1: n = 28; year 2: n = 20; year 3: n = 10) and the
Tat 30 μg, 5x group (year 1: n = 28; year: 2 n = 19; year 3: n = 9); (B) OBS subjects (year 1: n = 38; year 2: n = 25). (C) Changes from baseline of
CD38+HLA-DR+/CD8+ at week 8, 12, 20 and 48 in vaccinees of the Tat 30 μg, 3x group (n = 28); and the Tat 30 μg, 5x group (n = 28). Data are
presented as mean values with standard error. A longitudinal analysis for repeated measurements was applied. P-values assess the values at year
1, 2, or 3 or week 8, 12, 20 or 48 after immunization versus baseline values.
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at least a positive anti-Tat humoral or cellular response at
any given time point during the study were defined “re-
sponders”. In particular, percentage of subjects producing
Anti-Tat Abs (responders) after Tat immunization was re-
ferred to patients who developed Abs within 24 weeks of
follow-up (time-points: 4, 8, 12, 16, 20, 24 weeks), while
the percentage of subjects with cellular responses was re-
ferred to patients with at least one positive response
within 48 weeks (time-points: 4, 8, 12, 20, 48 weeks).
Ninety-five percent confidence intervals were esti-
mated for the primary endpoints and comparison amongtreatment groups was performed using the Odds ratio.
Cochran-Armitage Trend test was used to evaluate the
association between increasing doses (7.5 or 30 μg) and
number of administrations (3 or 5 times) with the per-
centage of subjects producing anti-Tat Abs (responders)
after immunization. Kaplan-Meier method was used to
assess the cumulative probability of anti-Tat Ab persist-
ence, by treatment groups and compared by the
Log-Rank test. Peak intensity of Abs and cellular re-
sponses was compared between Tat doses by Wilcoxon
rank-sum test. McNemar’s and Wilcoxon signed-rank
tests were used to compare pre-post immunization
Figure 14 NK cells in immunized with Tat at the 30 μg doses or in OBS subjects. Changes from baseline of NK cells/μl at years 1, 2 and 3 in
(A) vaccinees of the Tat 30 μg, 3x (year 1 n = 37; year 2 n = 27; year 3: n = 18); and the Tat 30 μg, 5x group (year 1: n = 37; year 2: n = 26; year 3:
n = 16); and (B) OBS subjects (year 1: n = 79; year 2: n = 42; year 3: n = 30). Data are presented as mean values with standard error. A longitudinal
analysis for repeated measurements was applied. P-values assess the values at year 1, 2 or 3 after immunization versus baseline values.
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respectively.
Longitudinal analysis for repeated measurements was
used to evaluate the changes from baseline of CD4+,
CD8+, B and NK cell number as well as naïve, Tem and
Tcm CD4+ and CD8+ T cell subsets at year 1, 2 or 3,
both overall or stratified by drug regimens (NNRTI/
NRTI- or PI-based). The same analysis was applied to
evaluate changes from baseline of CD38+HLA-DR+/CD8+
T cells and NK cells at year 1, 2 or 3 or by weeks at year 1
stratified by the two 30 μg treatment groups.
Changes from baseline of naïve, Tem and Tcm CD4+
or CD8+ T cell percentages in OBS subjects were calcu-
lated considering as baseline the first visit at which these
parameters were evaluated. The same previous analysis
was applied to evaluate the changes from baseline of
HIV-1 DNA load stratified by treatment groups and
antiretroviral regimens. To estimate the decay rate of
HIV-1 DNA, a longitudinal analysis was performedTable 10 Clinical study protocol and amendments
Study protocol Date Sample size Fol
Original 12/02/2008 128 48 w
First amendment 24/11/2009 160 144
Second amendment 20/07/2012 160 48 wusing a random-effects regression model with first order
kinetic effect; the slope of the decay was determined
from a plot of log10 DNA (copies/10
6 CD4+ T cells)
versus time in weeks [84]. Relationship between the Tat-
mediated Env entry in DC and anti-Tat Ab binding titers
was assessed by the generalized estimating equations
with adjustment for repeated measures in the same pa-
tient, after controlling normality assumption of variables
distribution (Saphiro-Wilk test). The percentage of DC
internalizing Env in the presence or absence of Tat with
sera from vaccinees was assessed by the Student’s t-test
(log10 transformation was performed to normalize the
data distribution). Neutralizing sera were defined as
those capable of inhibiting Env internalization into DC
in the presence of Tat by at least 50% as compared to
baseline values. The percentage of subjects positive for
neutralizing activity was compared between anti-Tat Ab
positive and negative individuals by the Fisher's Exact
test. Pearson correlation coefficient was used to assesslow-up Major inclusion criteria
eeks Viral load <50 copies/ml in the last 6 months; No history
of virologic rebound; CD4+ T cell counts ≥400 cells/μl;
Pre-HAART CD4+ nadir >250 cells/μl No history of
AIDS-related opportunistic or neoplastic disease; No
concomitant treatment for HBV or HCV infections
weeks Viral load <50 copies/ml in the last 6 months; Allowed
history of virologic rebound; CD4+ T cell counts ≥200
cells/μl; Any pre-HAART CD4+ nadir; Allowed history of
AIDS-related opportunistic or neoplastic disease; HBV or
HCV co-infections were allowed
eeks Same criteria of the first amendment
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Ab titers at week 48. Changes from baseline of HIV-1
DNA in subjects with anti-Tat Abs and neutralizing ac-
tivity were evaluated by analysis of variance for repeated
measurements.
No direct statistical comparison was done between
vaccinees and OBS subjects, since they belong to two
different studies. Statistical analyses were carried out at
two-sided with a 0.05 significance level, using SAS® soft-
ware, version 9.2 (SAS Institute, Cary, NC, US).
Ethical approval
Studies in humans were conducted according to the
principles of the Declaration of Helsinki and all subjects
signed an informed consent prior to enrollment. The ISS
T-002 clinical trial was approved by the competent
authority (General Director of the Coordinator Clinical
Center, Policlinico of Modena, Modena) and by the
Ethics Committees of each participating clinical center
(Policlinico of Modena, Modena; Arcispedale S. Anna,
Ferrara; Istituti Fiosterapici Ospitalieri San Gallicano,
Rome; Policlinico of Bari, Bari; Ospedale S.M. Goretti
Latina; Fondazione S. Raffaele, Milan; Ospedale S. Maria
Annunziata Florence; Ospedale Luigi Sacco, Milan;
Spedali Civili, Brescia; Ospedale A. di Savoia, Turin).
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Additional file 1: Table S1. ISS T-002: adverse events certainly, possibly
or probably related to immunization up to 48 weeks, classified by
MedDRA SOC and preferred term.
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